Notícias ARS Pharmaceuticals Inc - SPRY | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
ARS Pharmaceuticals Inc (SPRY)
ARS Pharmaceuticals Inc (SPRY) Notícias

ARS Pharmaceuticals Inc (SPRY)

14,53

0,16

(1,11%)

Fechado 28 Novembro 6:00PM

Atrasado por 15 minutos

14,59

0,06

(0,41%)

Após o horário de negociação: 9:59PM

Atrasado por 15 minutos

Ferramentas de nível profissional para investidores individuais.

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results

ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA’s CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand

ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)

ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

ARS Pharmaceuticals Reviews Recent Clinical Updates and Commercial Opportunity at neffy® Investor Day

Form 8-K - Current report

ARS Pharmaceuticals to Participate in the Leerink Partners Global Biopharma Conference 2024

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

ARS Pharmaceuticals announces neffy® meets primary endpoints and shows rapid symptom control in Phase 2 urticaria clinical study

ARS Pharmaceuticals to Host Virtual neffy® Investor Day on March 7, 2024

2
3
4
Próxima

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

ARS Pharmaceuticals

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições